B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

MAOB

MOLECULAR TARGET

monoamine oxidase B

UniProt: P27338NCBI Gene: 412919 compounds

MAOB (monoamine oxidase B) is targeted by 19 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MAOB

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Iproniazid4.3778
2Moclobemide2.7114
3Phenelzine1.956
4Pioglitazone1.956
5Genistein1.795
6Farnesol1.614
7Zonisamide1.614
8Idazoxan1.393
9Vitamin K 31.393
10Troglitazone1.393
11auraptene1.102
12hispidol1.102
13Linezolid1.102
14Apigenin 5,7,4'-trihydroxy-flavone,0.691
15chrysin0.691
16Resveratrol0.691
17Emodin Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as0.691
18Fentanyl0.691
19Rilmenidine Oxazole derivative that acts as0.691

About MAOB as a Drug Target

MAOB (monoamine oxidase B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 19 compounds with documented MAOB interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MAOB inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.